APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice

Özge Uluçkan; Mark C. Eagleton; Desiree H. Floyd; Elizabeth A. Morgan; Angela C. Hirbe; Matthew Kramer; Nikki Dowland; Julie L. Prior; David Piwnica‐Worms; Soon Seog Jeong; Ridong Chen; Katherine Weilbaecher

doi:10.1002/jcb.21709

journal article Feb 07, 2008

APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice

Özge Uluçkan Mark C. Eagleton Desiree H. Floyd Elizabeth A. Morgan Angela C. Hirbe Matthew Kramer Nikki Dowland Julie L. Prior David Piwnica‐Worms Soon Seog Jeong Ridong Chen

Katherine Weilbaecher

Journal of Cellular Biochemistry Vol. 104 No. 4 pp. 1311-1323 · Wiley

View at Publisher Save 10.1002/jcb.21709

Abstract

AbstractPlatelets contribute to the development of metastasis, the most common cause of mortality in cancer patients, but the precise role that anti‐platelet drugs play in cancer treatment is not defined. Metastatic tumor cells can produce platelet αIIbβ3 activators, such as ADP and thromboxane A2 (TXA2). Inhibitors of platelet β3 integrins decrease bone metastases in mice but are associated with significant bleeding. We examined the role of a novel soluble apyrase/ADPase, APT102, and an inhibitor of TXA2 synthesis, acetylsalicylic acid (aspirin or ASA), in mouse models of experimental bone metastases. We found that treatment with ASA and APT102 in combination (ASA + APT102), but not either drug alone, significantly decreased breast cancer and melanoma bone metastases in mice with fewer bleeding complications than observed with αIIbβ3 inhibition. ASA + APT102 diminished tumor cell induced platelet aggregation but did not directly alter tumor cell viability. Notably, APT102 + ASA treatment did not affect initial tumor cell distribution and similar results were observed in β3−/− mice. These results show that treatment with ASA + APT102 decreases bone metastases without significant bleeding complications. Anti‐platelet drugs such as ASA + APT102 could be valuable experimental tools for studying the role of platelet activation in metastasis as well as a therapeutic option for the prevention of bone metastases. J. Cell. Biochem. 104: 1311–1323, 2008. © 2008 Wiley‐Liss, Inc.

Topics

No keywords indexed for this article. Browse by subject →

References

57

[1]

10.1038/nbt1281

[2]

Akl EA "Oral anticoagulation for prolonging survival in patients with cancer" Cochrane Database Syst Rev (2007)

[3]

10.1038/sj.bjp.0705606

[4]

10.1055/s-0037-1613114

[5]

10.1161/01.cir.101.10.1206

[6]

10.1073/pnas.2234372100

[7]

10.1016/0003-2697(88)90485-x

[8]

10.1097/00003086-200303000-00002

[9]

10.1172/jci200422123

[10]

Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets

Habib Boukerche, Odile Berthier‐Vergnes, Franclois Penin et al.

British Journal of Haematology 10.1111/j.1365-2141.1994.tb06736.x

[11]

10.1056/nejmoa050434

[12]

10.1055/s-0037-1615666

[13]

10.1182/blood-2004-02-0434

[14]

Castelli R "Cancer and thromboembolism: From biology to clinics" Minerva Med (2006)

[15]

10.1016/s0002-9343(00)00683-5

[16]

10.1074/jbc.m208778200

[17]

10.7326/0003-4819-146-5-200703060-00009

[18]

10.1055/s-2002-20562

[19]

10.1002/ijc.11479

[20]

10.1007/bf00047657

[21]

10.1053/j.seminoncol.2004.03.040

[22]

10.1159/000046587

[23]

Grignani G "Platelets in tumor metastasis: Generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential" Blood (1988) 10.1182/blood.v71.4.844.844

[24]

10.1002/1097-0142(20000615)88:12 <2892::aid-cncr2>3.0.co;2-y

[25]

10.1186/ar2213

[26]

10.1182/blood-2006-09-048686

[27]

10.1096/fj.00-0395com

[28]

10.1056/nejm199612123352401

[29]

10.1182/blood-2004-03-1047

[30]

10.1080/10739680590925493

[31]

10.1038/sj.bjp.0704343

[32]

Karpatkin S "The role of tumor‐induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis" Prog Clin Biol Res (1988)

[33]

10.1002/ijc.2910310411

[34]

10.1055/s-2005-869528

[35]

10.1182/blood-2006-07-028282

[36]

10.1124/jpet.105.098384

[37]

10.1038/nrc867

[38]

10.1055/s-2004-833476

[39]

Nierodzik ML "Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo" Cancer Res (1992)

[40]

10.1046/j.1365-2141.1996.d01-1494.x

[41]

10.1182/blood-2004-06-2272

[42]

10.1161/01.cir.0000091201.39590.cb

[43]

10.1016/0092-8674(91)90451-4

[44]

10.1093/ajhp/62.22_supplement_5.s4

[45]

10.1056/nejmra030831

[46]

10.1146/annurev.cb.11.110195.003001

[47]

10.1023/a:1011184706281

[48]

10.1158/1541-7786.395.2.7

[49]

10.1186/bcr1398

[50]

10.1182/blood.v98.4.1055

Showing 50 of 57 references

Cited By

55

The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities

Christiana M. Neophytou, Myrofora Panagi · 2021

Cancers

Purinergic signalling in the musculoskeletal system

Geoffrey Burnstock, Timothy R. Arnett · 2013

Purinergic Signalling

Deadly allies: the fatal interplay between platelets and metastasizing cancer cells

Luise Erpenbeck, Michael P. Schön · 2010

Blood

Metrics

55

Citations

57

References

Details

Published: Feb 07, 2008
Vol/Issue: 104(4)
Pages: 1311-1323
License: View

Authors

Katherine Weilbaecher

Cite This Article

Özge Uluçkan, Mark C. Eagleton, Desiree H. Floyd, et al. (2008). APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Journal of Cellular Biochemistry, 104(4), 1311-1323. https://doi.org/10.1002/jcb.21709

APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice

You May Also Like